#United States #Denver #Chronic Hepatitis D #EIT Pharma #Lonafarnib

EIT Pharma Presents Data on Lonafarnib at AASLD 2026

EIT Pharma, Inc., known for its dedication to tackling infectious diseases, has made headlines at this year's American Association for the Study of Liver Diseases (AASLD) meeting held in Denver, Colorado. The biotechnology company revealed extended analyses from their extensive phase 3 D-LIVR trial, which is recognized as the largest study on chronic hepatitis D (CHD) to this date, enrolling over 400 participants across 21 countries.

Highlighted Findings of the D-LIVR Trial

In their presentation, EIT Pharma primarily focused on comparing the efficacy of lonafarnib-based therapies with a placebo. The results were promising, showcasing sustained benefits even after the cessation of treatment. These findings bolster the ongoing development of lonafarnib as a reliable finite treatment option for patients battling chronic hepatitis D.

Dr. Leen Kawas, the company’s CEO, expressed satisfaction in presenting the trial's extended analysis, stating, "The Liver Meeting® serves as an essential platform for hepatology experts to discuss advancements and strategies for improving patient care. Our findings emphasize the potential of a lonafarnib-based regimen to offer lasting advantages to those suffering from CHD."

Details of the Presentation

The study analyzed the durability of treatment responses and the rise of new composite responders post-treatment. Led by Professor Tarik Asselah, MD, PhD, the presentation was termed "Durable and newly emergent treatment response during a 24-week follow-up in a finite lonafarnib treatment regimen extended analyses from the phase 3 D-LIVR trial." This session not only informed attendees regarding treatment outcomes but also emphasized the value in patient management beyond simple viral suppression.

During the meeting, EIT Pharma engaged in scientific discussions with over 20 key opinion leaders from the U.S. and abroad, focusing on essential topics such as identifying clinical markers crucial to liver health outcomes. Dr. Xue Hua, Chief Development Officer, underscored the importance of these interactions, stating, "Our discussions with hepatitis D experts assist in outlining our research direction to ensure data signifies value against critical health markers. Our commitment is to develop therapies which are genuinely meaningful for patients and relevant for healthcare providers."

Understanding Lonafarnib's Role

Lonafarnib is an investigational oral treatment option being studied for chronic hepatitis D. Designed to target a vital phase in the hepatitis D virus lifecycle, lonafarnib stands out as the only oral therapeutic agent presently in late-stage clinical trials for this condition. However, it should be noted that lonafarnib has yet to receive approval from the U.S. Food and Drug Administration or any other regulatory body for chronic hepatitis D treatment, meaning its safety and effectiveness have yet to be confirmed.

About EIT Pharma

Established with a mission to advance therapies for infectious diseases, EIT Pharma remains dedicated to addressing significant unmet medical needs. The company's strategic focus revolves around developing an array of programs aimed at combatting serious infectious diseases through rigorous scientific methods and a patient-centered approach. By emphasizing the translation of scientific innovation into real-world patient benefits, EIT Pharma is paving the way for impactful healthcare solutions.

Looking Ahead

As the field of hepatitis D treatment continues to evolve, EIT Pharma’s initiative holds promise for revolutionizing patient care. The ongoing trials and forthcoming results could potentially reshape the standards of treatment practice, highlighting the importance of developing effective and finite therapeutic options for chronic diseases. The future looks hopeful as EIT Pharma strengthens its commitment to providing innovative therapies for enduring health challenges.